CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Norwood Immunology Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Norwood Immunology Ltd.
P.O. Box 211
Phone: +44 207 466 5000p:+44 207 466 5000 Patterson Lakes, Victoria  3197  Australia Ticker: NIM NIM
This company is no longer actively traded on any major stock exchange.
Business Summary
Norwood Immunology Limited is engaged in developing and commercializing of technologies and intellectual property associated with the rejuvenation of the immune system (involving the re-growth of the thymus, generation of T cells and improved bone marrow function) and the development of adjuvanted virosomal vaccines. The Company operates in two segments: Immunology and Virosomal Vaccines. Immunology is engaged in improvement of immunity involving the re-growth of the thymus, generation of T cells and improved bone marrow function. Virosomal Vaccines is a method of making virosomes, as well as the combination of an adjuvant (immune response stimulator) in the membrane of the virosome that targets them specifically to antigen presenting cells or B cells, to improve the efficacy of vaccines. In April 2009, Mymetics Corporation acquired Bestewil Holding B.V. and its subsidiary, Virosome Biologicals B.V., from the Company.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20086/30/2008Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Peter J.Hansen 63 1/1/2005
Chief Executive Officer, Executive Director Richard F.Williams 51 10/31/2003
Chief Scientific Officer, Director Richard L.Boyd 57 12/21/2007 12/21/2007
Company Secretary Jeffrey H.Bell 36 8/31/2006 10/31/2003
Chief Scientific Officer of Virosome Biologicals B.V. A. J.Stegmann

Business Names
Business Name
NIM
Norwood Immunology Ltd.

General Information
Number of Employees: 5 (As of 6/30/2006)
Outstanding Shares: 228,241,387 (As of 12/31/2008)
Stock Exchange: SEA


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, July 23, 2023